EMCURE Stock Overview

Engages in the developing, manufacturing, and marketing pharmaceutical products worldwide. More details

EMCURE fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 25.31% per year

Risk Analysis

No risks detected for EMCURE from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Emcure Pharmaceuticals Limited Competitors

NATCO Pharma

NSEI:NATCOPHARM

₹253.8b

Gland Pharma

NSEI:GLAND

₹292.0b

J. B. Chemicals & Pharmaceuticals

BSE:506943

₹294.3b

Suven Pharmaceuticals

NSEI:SUVENPHAR

₹301.7b

Price History & Performance

Summary of share price highs, lows and changes for Emcure Pharmaceuticals
Historical stock prices
Current Share Price	₹1,372.90
52 Week High	₹1,580.00
52 Week Low	₹1,225.00
Beta	0
1 Month Change	4.47%
3 Month Change	-4.95%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.01%

Recent updates

Shareholder Returns

	EMCURE	IN Pharmaceuticals	IN Market
7D	1.0%	0.8%	-4.2%
1Y	n/a	39.7%	19.1%

Return vs Industry: Insufficient data to determine how EMCURE performed against the Indian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how EMCURE performed against the Indian Market.

Price Volatility

Is EMCURE's price volatile compared to industry and market?
EMCURE volatility
EMCURE Average Weekly Movement	5.1%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.0%
10% least volatile stocks in IN Market	4.1%

Stable Share Price: EMCURE has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: Insufficient data to determine EMCURE's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	10,852	Satish Mehta	www.emcure.com

Emcure Pharmaceuticals Limited engages in the developing, manufacturing, and marketing pharmaceutical products worldwide. It offers products in various therapeutic areas, such as gynecology, cardiovascular, anti-infectives, HIV antivirals, respiratory, gastrointestinal, pain and analgesics, blood related, oncology/anti-neoplastics, anti-diabetic, hormones, neurology/central nervous system, dermatology, and other areas, as well as vitamins, minerals, and nutrients. The company also develops products across various platforms, including chiral molecules, complex APIs, orals, iron products, photo-chemistry products, liposomal and lyophilized injectables, high potency drugs, biotherapeutics, and novel drug delivery systems.

Emcure Pharmaceuticals Limited Fundamentals Summary

How do Emcure Pharmaceuticals's earnings and revenue compare to its market cap?
EMCURE fundamental statistics
Market cap	₹260.07b
Earnings (TTM)	₹5.67b
Revenue (TTM)	₹72.56b

45.8x

P/E Ratio

3.6x

P/S Ratio

Is EMCURE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EMCURE income statement (TTM)
Revenue	₹72.56b
Cost of Revenue	₹28.25b
Gross Profit	₹44.31b
Other Expenses	₹38.64b
Earnings	₹5.67b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	29.95
Gross Margin	61.07%
Net Profit Margin	7.82%
Debt/Equity Ratio	21.9%

How did EMCURE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 06:24
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Emcure Pharmaceuticals Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Alok Dalal	Jefferies LLC
Bansi Desai	J.P. Morgan
Sanjeev Prasad	Kotak Securities (Institutional Equities)